Humana Inc.
HUM Healthcare Healthcare Plans
Humana Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.7 billion, up 10.1% from fiscal 2024. In the quarter to June 2026, revenue grew 26.2%, EPS grew 27.9%, free cash flow grew 58.5% and total debt rose 13.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five; insiders bought in the last twelve months.
Follow HUM
Humana Inc. (HUM) EV/EBITDA
As of 16 October 2026, Humana Inc. (HUM) trades at a EV/EBITDA of 11.5×. Over the past ten years it has ranged from 3.6× (March 2026) to 15.9× (December 2021); the current reading is higher than 89% of that period. That is in line with the Healthcare Plans industry median of 11.5× and above the Healthcare sector median of 9.2×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 6.8× | 9.29% |
| FY2024 | 6.2× | (37.09%) |
| FY2023 | 9.9× | (17.49%) |
| FY2022 | 11.9× | (17.10%) |
| FY2021 | 14.4× | 84.73% |
| FY2020 | 7.8× | (26.17%) |
| FY2019 | 10.6× | 15.97% |
| FY2018 | 9.1× | 56.14% |
| FY2017 | 5.8× | (41.89%) |
| FY2016 | 10.0× | 33.94% |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Jun 2026 | 10.9× | 175.04% |
| Mar 2026 | 4.0× | (41.38%) |
| Dec 2025 | 6.8× | 16.33% |
| Sep 2025 | 5.8× | 17.03% |
| 42 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| CNC Centene Corporation compare | n/m |
| CLOV Clover Health Investments, Corp. compare | n/m |
| CI Cigna Group compare | 8.3× |
| CVS CVS Health Corporation compare | 8.9× |
| OSCR Oscar Health, Inc. compare | 9.4× |
| ELV Elevance Health, Inc. compare | 9.8× |
| HUM Humana Inc. | 11.5× |
| MOH Molina Healthcare, Inc compare | 15.3× |
| UNH UnitedHealth Group Incorporated compare | 15.5× |
| Healthcare Plans industry median | 11.5× |
| Healthcare sector median | 9.2× |
| Market median | 11.0× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on HUM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement